Efficacy of recombinant growth hormone therapy in children born small for gestational age (SGA): a retrospective analysis

Introduction

Children born small for gestational age (SGA) present with a birth weight or length below -2 standard deviations (SD) relative to population norms for gestational age and sex. In Poland, such patients are eligible for recombinant human growth hormone (rhGH) therapy reimbursed by the National Health Fund.